Christian Winther Eskelund, MD
Multivariate analysis of the Nordic MCL2 and MCL3 trials showed that the presence of TP53
mutations predicted worse overall survival (OS) in younger patients with mantle cell lymphoma (MCL).
Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemotherapy [published online August 17, 2017]. Blood. doi: 10.1182/blood-2017-04-779736.
... to read the full story